Fig. 3

Treatment recommendations for case 2, a high-risk astrocytic LGG, in 12/2016 (left panel) and 2015 (right panel). When comparing the treatment recommendations before and after the publication of RTOG 9802, we saw a trend towards an active treatment also for high –risk astrocytic LGGs (53 vs. 42%). When patients received a recommendation for active treatment, this was most likely to be radiotherapy followed by PCV (19% in 2016 vs. 16% in 2015) or a radiochemotherapy with temozolomide (5% in 2015 vs. 16% in 2016)